产品说明书

Gatifloxacin

Print
Chemical Structure| 112811-59-3 同义名 : BMS-206584;AM-1155;BMS 206584-01;CG5501;PD135432
CAS号 : 112811-59-3
货号 : A142500
分子式 : C19H22FN3O4
纯度 : 98%
分子量 : 375.394
MDL号 : MFCD00895399
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 2 mg/mL(5.33 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 1 mg/mL(2.66 mM)，配合低频超声助溶
动物实验配方：
生物活性
靶点

  • Topoisomerase
描述 Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial type II topoisomerases (IC50=13.8μg/ml for S. aureus topoisomerase IV; IC50=0.109μg/ml for E. coli DNA gyrase) but shows low inhibition against HeLa cell topoisomerase II (IC50=265μg/ml)[3]. Gatifloxacin (subcutaneous injection; 100 mg/kg; 3 times a day; 30 days) significantly decreases the number of lesions in mouse footpad with Nocardia brasiliensis[4].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03625739 - Recruiting December 31, 2026 China ... 展开 >> Beijing Children's Hospital of Capital Medical University Recruiting Beijing, China Contact: Adong Shen, Master    13370115087    shenad16@hotmail.com 收起 <<
NCT00831961 - Completed - United States, Tennessee ... 展开 >> Vanderbilt Eye Institute Nashville, Tennessee, United States, 37232 收起 <<
NCT02099240 Osteomyelitis Early Phase 1 Recruiting September 2019 United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.32mL

2.66mL

1.33mL

26.64mL

5.33mL

2.66mL
参考文献

[1]Dawis MA, Isenberg HD, et al. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J Antimicrob Chemother. 2003 May;51(5):1203-11.

[2]Takei M, Fukuda H, et al. Inhibitory activities ofgatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother. 1998 Oct;42(10):2678-81.

[3] Takei M, Fukuda H, Yasue T, Hosaka M, Oomori Y. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother. 1998 Oct;42(10):2678-81.

[4]Daw-Garza A, Welsh O, Said-Fernández S, Lozano-Garza HG, Waksman de Torres N, Rocha NC, Ocampo-Candiani J, Vera-Cabrera L. In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis. Antimicrob Agents Chemother. 2008 Apr;52(4):1549-50.